Preparation of highly specific radioactivity [ 18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography

A straightforward method for the preparation of no-carrier-added (n.c.a.) [ 18F]flumazenil via standard nucleophilic radiofluorination of the corresponding nitro-analog Ro 15-2344 has been developed. The labeling was performed by employing the K 18F/kryptofix complex in DMF at 160°C for 30 min and e...

Full description

Saved in:
Bibliographic Details
Published inNuclear medicine and biology Vol. 32; no. 2; pp. 109 - 116
Main Authors Ryzhikov, Nikolaj N., Seneca, Nicholas, Krasikova, Raisa N., Gomzina, Natalia A., Shchukin, Evgeny, Fedorova, Olga S., Vassiliev, Dmitrij A., Gulyás, Balázs, Hall, Håkan, Savic, Ivanka, Halldin, Christer
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A straightforward method for the preparation of no-carrier-added (n.c.a.) [ 18F]flumazenil via standard nucleophilic radiofluorination of the corresponding nitro-analog Ro 15-2344 has been developed. The labeling was performed by employing the K 18F/kryptofix complex in DMF at 160°C for 30 min and equimolar ratio [K/K2.2.2] +18F −/precursor. Under these conditions, an 18F incorporation rate into flumazenil was in the range of 55–60%. The final product was isolated by HPLC purification within a total synthesis time of 75 min and a radiochemical yield of about 30% (EOB). Human post-mortem whole-hemisphere autoradiography of brain sections demonstrated selective uptake of the radioligand in the areas of high density of the central benzodiazepine receptors (BZR). PET studies in a cynomolgus monkey and metabolite studies by HPLC demonstrated similar results by [ 18F]flumazenil as for [ 11C]flumazenil. In blocking experiments, almost all radioactivity was inhibited by the addition of unlabeled flumazenil. [ 18F]Flumazenil is a suitable radioligand for PET assessment of the BZR.
ISSN:0969-8051
1872-9614
DOI:10.1016/j.nucmedbio.2004.11.001